RT/PBT Advanced Practitioner R&D Therapeutic Radiographer

University College London Hospitals NHS Foundation Trust; City of Westminster; On-site; GBP 52,000 - 72,000; Full time

Job summary

The Radiotherapy and Proton Beam Therapy Advanced Practitioner Research and Development Therapeutic Radiographer role offers an exciting opportunity to play a key role in research and development in Radiotherapy services at UCLH.

They will be a crucial member of the R&D team, involved in service development projects as per the departmental workplan, collaborative research projects with our academic partner UCL and to facilitate the opening of Radiotherapy clinical trials.

Qualifications

• Relevant professional radiography work experience preferred.
• Experience in research or clinical trials advantageous.

Responsibilities

• Manage the clinical implementation of Radiotherapy Trials and ECIP Portfolio.
• Implement Radiotherapy studies and ECIP studies into clinical practice in a timely manner.
• Develop protocols with the radiotherapy MDT and maintain appropriate databases.
• Ensure trial data and CRFs are completed within time guidelines.

Job description

Radiotherapy and Proton Beam Therapy Advanced Practitioner Research and Development Therapeutic Radiographer

This role offers an exciting opportunity to play a key role in research and development (R&D) in Radiotherapy services at UCLH. They will be a crucial member of the R&D team, involved in service development projects as per the departmental workplan, collaborative research projects with our academic partner UCL and to facilitate the opening of Radiotherapy clinical trials. In addition, the post holder will take a lead role in the implementation and maintenance of the Evaluative Commissioning in Protons (ECIP) portfolio. The roles involve the collation and analysis of research data and the dissemination of findings locally, nationally, and internationally via presentations and publications.

UCLH and UCL are seeking committed individuals with the energy and focus to continue building on the existing service of excellence and deliver the projects to completion.

Main duties of the job

• To manage the clinical implementation of the Radiotherapy Trials and ECIP Portfolio
• To implement selected Radiotherapy studies and ECIP studies into clinical practice in a timely manner.
• To ensure that trial protocols, processes and timelines are adhered to. To develop protocols as part of the wider radiotherapy MDT for in-house studies
• To assist in the development and maintenance of databases as appropriate
• To ensure that trial data and Case Report Forms (CRFs), as required, are completed within appropriate time guidelines

University College London Hospitals NHS Foundation Trust (UCLH) is one of the most complex NHS trusts in the UK, serving a large and diverse population. We provide academically led acute and specialist services, to people from the local area, from throughout the United Kingdom and overseas. Our vision is to deliver top-quality patient care, excellent education, and world-class research.

We provide first-class acute and specialist services across eight sites:

• University College Hospital (incorporating the Elizabeth Garrett Anderson Wing)
• National Hospital for Neurology and Neurosurgery
• Royal National ENT and Eastman Dental Hospital
• University College Hospital Grafton Way Building
• Royal London Hospital for Integrated Medicine
• University College Hospital Macmillan Cancer Centre
• The Hospital for Tropical Diseases
• University College Hospital at Westmoreland Street

We are dedicated to the diagnosis and treatment of many complex illnesses. UCLH specialises in women's health and the treatment of cancer, infection, neurological, gastrointestinal and oral disease. It has world class support services including critical care, imaging, nuclear medicine and pathology.

We are committed to sustainability and have pledged to become a carbon net zero health service, embedding sustainable practice throughout UCLH. We have set an ambitious target of net zero for our direct emissions by 2031 and indirect emissions by 2040.